Peregrine shares continue roller coaster ride on revised cancer data; Chiesi bids for remaining Cornerstone shares;

 @FierceBiotech: If you missed it yesterday, check out @RyanMFierce's feature on FierceBiotechIT.com: Top 10 Biotech Techies, 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Interesting biotech model: NC development team nabs $5M angel tranche for their latest biotech play. Story | Follow @JohnCFierce

> Shares of Peregrine Pharmaceuticals ($PPHM) continued on a roller-coaster ride yesterday after the biotech disappointed investors with a revised look at midstage lung cancer data for bavituximab. Peregrine has been trying to repair the damage inflicted by its announcement 5 months ago that there were major discrepancies in their data. A few weeks ago the company said that the discrepancies were limited to the placebo and the 1 mg/kg treatment arms. Story

> Chiesi Farmaceutici SpA is making a bid to buy the 40% of Cornerstone Therapeutics ($CRTX) shares it doesn't already own. Release

> Curis has lured ACT Biotech founder Ali Fattaey into a new job as president and COO. Report

> Selexis SA announced today that Amgen ($AMGN) has expanded their R&D license agreement to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line for research and development. Release

Pharma News

@FiercePharma: Chinese government plans to cut the number of drug wholesalers to 3K from 13K. Pharma stocks there rose on the news. More | Follow @FiercePharma

@EricPFierce: Gilead, Teva now making nice over Viread patent, ending years of litigation. News | Follow @EricPFierce

@AlisonBFierce: HealthMap has expanded its reach, allowing people to search for any of 11 vaccines available near their home. Story | Follow @AlisonBFierce

> Gilead, Teva wrap up Viread patent fight. News

> Italian antitrust agency probes alleged Roche-Novartis cartel. Report

> Study: ED drugmakers aren't properly policing their TV ads. Story

Medical Device News

 @FierceMedDev: Dune gains CE mark for next-gen breast cancer Dx tool. News | Follow @FierceMedDev

 @MarkHFierce: Hmm, the second med device venture funding in two days. This time, a focus on uterine fibroid ablation. Release | Follow @MarkHFierce

 @DamianFierce: Thanks to investor excitement, Life Technologies might now be too pricey for a sale. More | Follow @DamianFierce

> Natera launches prenatal diagnostic with big Quest co-sign. Story

> Medtronic halves estimate of device tax hit. Item

Drug Delivery News

> Lentigen's stem-cell delivery for brain tumors nets FDA orphan status. News

> PolyActiva seeks drug partner for new intraocular delivery implant. Report

> Oramed presses forward into PhII with oral insulin pill. Story

> EpiVax, Novozymes fuse drug, delivery protein with $3B market at hand. Item

Biomarkers News

> NIH pours $900K into Parkinson's biomarker research. News

> Alzheimer's biomarkers indicate dementia advancement. More

> Mayo study spotlights new biomarkers for quick kidney injury alert. Report

> NYU investigative team on the trail of PTSD biomarkers. Article

> Nanomix plans test of triple biomarker heart attack Dx. Story

And Finally… Researchers from Göttingen and Bonn have shed new light on the chemical compound known as "methylene blue," a possible drug candidate for Alzheimer's. Release

 

Suggested Articles

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets.